Skip to content

Author

M. Sarfraz

1 paper indexed here

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Review Open access 2026

Resmetirom: A New FDA-approved Drug as a Targeted Therapeutic Strategy in Metabolic Dysfunction Associated Steatohepatitis: Translational Evidence from Current Clinical Trials.

Metabolic dysfunction-associated steatohepatitis (MASH) represents a significant global health burden, affecting 3-5% of the population and projected to become a leading cause of liver transplantation by 2030. This review examines Resmetirom, the first FDA-approved drug for non-cirrhotic MASH with moderate to severe he...

Ghulam Hassam U. Din Tarrar, Syed Shafaat Hussain, M. Sarfraz et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.